Arcutis Biotherapeutics had its Relative Strength (RS) Rating upgraded from 88 to 91 Monday.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary rating tracks share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best-performing stocks typically have an RS Rating of above 80 at the beginning of a new climb.
Arcutis Biotherapeutics is building a consolidation with a 17.75 buy point. See if it can clear the breakout price in heavy trade.
Arcutis Biotherapeutics posted 0% earnings growth in its most recent report, while sales growth came in at 33%.
Arcutis Biotherapeutics earns the No. 61 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
